## DESCRIPTION

This activity will convene community-based providers and academic oncologists to improve the care and outcomes of patients with hematologic malignancies. To reach this goal, this activity will address early treatment options and medical advances to reduce cancer-related deaths, including CAR T-cell therapy, other novel immunotherapies, and targeted agents for the state-of-the-art management of newly diagnosed and relapsed blood cancers. It will keep all healthcare professionals who care for patients with hematologic malignancies abreast of the latest scientific updates, innovative ideas, and the timeliest issues related to patients with these diseases.

## TARGET AUDIENCE

This activity is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to treating hematologic cancers.

## LEARNING OBJECTIVES

After this activity, participants will be able to:

- Recall the optimal patient selection, timing, and regimens for stem cell transplantation;
- Recognize the optimal sequencing of novel therapeutic options in the care of lymphoma patients with the incorporation of recent advancements in the field;
- Identify available clinical trial options and other approaches to patients with relapsed/refractory disease;
- State the role of existing and emerging targeted agents in leukemias and myeloid neoplasms;
- Discuss how to appropriately sequence treatment in multiple myeloma, from the use of frontline multi-drug combinations to the role of CAR T and bispecific antibodies in relapsed/refractory disease;
- Illustrate how cutting-edge data presented at the 2023 Annual Meeting of the American Society of Hematology can apply to clinical practice;
- Explain how to diagnose and treat common benign hematologic diseases with newly approved therapies;
- Interpret emerging clinical trial data in the context of CAR T-cell therapy for lymphoid malignancies.

## ACCREDITATION AND CREDIT DESIGNATION

**Physician Credit**
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 6.25 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nursing Credit**
University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Participants who successfully complete the entire activity and complete an evaluation form will earn 6.25 contact hours.

**American Board of Internal Medicine MOC II Credit**
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**American Board of Pediatrics MOC Part II Credit**
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 MOC points in the American Board of Pediatrics's (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

**Other Participant Credit**
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME, please consult your professional licensing board.

## EDUCATIONAL GRANTS/COMMERCIAL SUPPORT

**Educational grant funding has been generously provided by:**
ADC Therapeutics
AstraZeneca Pharmaceuticals

**We also thank our exhibitors:**

AbbVie
Adaptive Biotechnologies
ADC Therapeutics
Agios Pharmaceuticals
Alexion
Amgen
Astellas Oncology
AstraZeneca
Autolus
Beigene
Blueprint Medicines
Bristol Myers Squibb
Daiichi Sankyo
GenMab
Geron
GlaxoSmithKline
Incyte
Janssen
Jazz Pharmaceuticals
Karyopharm
Kite Pharma
Leukemia & Lymphoma Society
Lilly
Menarini Stemline
Merck
Morphosys
Novartis
Omeros
Pfizer – Hematology & Oncology
Pfizer – Precision Medicine
Pharmacosmos
Therapeutics
Pharmacyclics
PharmaEssentia
Rigel
Sanofi – Hematology & Oncology
Sanofi - Transplant
Servier
Sobi – Gamifant
Sobi - Hematology
Taiho Oncology
Takeda – Oncology
University of Chicago Staff

## DISCLOSURE DECLARATIONS

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of the content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships before the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

## COURSE FACULTY

**The following individuals have no relevant financial relationships with ineligible companies to disclose:**

| | | |
|---|---|---|
| Joseph Cannova, MD, PhD | Rafael Madero Marroquin, MD | Brooke Rixon, MHA |
| Luca Capicchioni, MSL | Rebecca Malloy, BSN | Alexandra Rojek, MD |
| Adam DuVall, MD, MPH | Mariam Nawas, MD | Asta Siugzdinis, BSN |

Michael Bishop, MD, has served as a consultant for Kite/Gilead, Novartis, BMS, and Incyte and on a speakers' bureau for Kite/Gilead, BMS, Incyte, Servier, Sanofi, AstraZeneca, GenMab, and ADC Therapeutics.

Kenneth Cohen, MD, has no relevant financial relationships with ineligible companies to disclose. Dr. Cohen will discuss investigational agents.

Jennifer Collins, PharmD, has no relevant financial relationships with ineligible companies to disclose. Dr. Collins will discuss the investigational/unapproved use of a commercial product.

Benjamin Derman, MD, has served as a consultant for Sanofi and Janssen and as a clinical trial reviewer for BMS.

Emily Dworkin, PharmD, BCOP, has served as a speaker for AbbVie.

Andrea Fadel, BSN, RN, OCN, has served on an advisory board for Kite. Andrea will discuss clinical trials on solid tumor cell therapy.

Andrzej Jakubowiak, MD, has served as a consultant and advisory board member for AbbVie, Amgen, BMS, GSK, Janssen, and Sanofi. Dr. Jakubowiak will discuss agents that are still in development and not yet approved but the results are relevant for discussion of ASH results.

Kaitlin Kelly, PharmD, has no relevant financial relationships to disclose. Dr. Kelly will discuss trials presented at ASH.

Justin Kline, MD, has served as a consultant for Merck and has received research support from Merck. Dr. Kline has served on an advisory board for Secura Bio, Gilead, Daiichi Sankyo, ADC Therapeutics, and Seagen and on a speakers' bureau for Gilead.

Satyajit Kosuri, MD, has served as a consultant for AbbVie, as a speaker for Sanofi, and as an advisory board member for Incyte.

Mylove Mortel, MSPH, RN, OCN, has served on an advisory board for BMS.

Olatoyosi Odenike, MD, has served on advisory boards for BMS, Incyte, Novartis, Servier, Blueprint Medicines, and Rigel Therapeutics. Dr. Odenike has received research funding from AstraZeneca, Loxo, Astex, BMS, and AbbVie.

Anand Patel, MD, has served on advisory boards for Sobi, AbbVie, and BMS and received research funding from Pfizer. Dr. Patel will discuss early phase trials of agents that are not yet FDA-approved.

Noopur Raje, MD, has served as a consultant and advisory board member for Celgene, Millenium Takeda, Amgen-Onyx, Novartis, Pfizer, Janssen, BMS, Merck, Bluebird, and Regeneron and on a steering committee for BMS. Dr. Raje has received research funding from Pfizer and Bluebird Bio. Dr. Raje will discuss CAR T and biospecifics in earlier lines of treatment.

Peter Riedell, MD, has served as a consultant and advisory board member for AbbVie, Novartis, BMS, ADC Therapeutics, Kite/Gilead, Nektar Therapeutics, CVS Caremark, Genmab, BeiGene, Janssen, and Pharmacyclics. He has served as a speaker for Kite Pharma and has received honoraria from Novartis. Dr. Riedell has received research support from BMS, Kite Pharma, Novartis, MorphoSys, and Genentech.

Sonali Smith, MD, has consulted for BMS, Gilead, and Ono Pharmaceuticals. Dr. Smith will discuss approved agents in unapproved settings and unapproved agents in development.

Michael Thirman, MD, has served as a consultant and advisory board member for AbbVie and AstraZeneca. Dr. Thirman has received grant funding from AbbVie.

The staff of the Center for Continuing Medical Education have no relevant financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

**DISCLAIMER**

The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.



Please Note: Requests to claim *AMA PRA Category 1 Credit*™ after three months will be subject to additional fees.